(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 4.32% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 4.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.54%.
Merck & Co's revenue in 2023 is $59,314,000,000.On average, 7 Wall Street analysts forecast MRK's revenue for 2023 to be $152,054,825,498,438, with the lowest MRK revenue forecast at $151,263,439,953,212, and the highest MRK revenue forecast at $152,801,455,127,953. On average, 7 Wall Street analysts forecast MRK's revenue for 2024 to be $161,025,728,407,999, with the lowest MRK revenue forecast at $158,616,161,333,746, and the highest MRK revenue forecast at $164,977,572,883,820.
In 2025, MRK is forecast to generate $170,789,461,255,944 in revenue, with the lowest revenue forecast at $167,242,989,520,916 and the highest revenue forecast at $176,565,660,446,952.